TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 2.2B
Gross Profit 1.6B 71.98%
Operating Income 846.0M 38.11%
Net Income 631.0M 28.42%
EPS (Diluted) $1.41

Balance Sheet Metrics

Total Assets 14.1B
Total Liabilities 9.4B
Shareholders Equity 4.7B
Debt to Equity 2.03

Cash Flow Metrics

Operating Cash Flow 567.0M
Free Cash Flow 438.0M

Revenue & Profitability Trend

Zoetis Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i9.3B8.5B8.1B7.8B6.7B
Cost of Goods Sold i2.7B2.6B2.5B2.3B2.1B
Gross Profit i6.5B6.0B5.6B5.5B4.6B
Gross Margin % i70.6%70.0%69.6%70.4%69.2%
Operating Expenses
Research & Development i686.0M614.0M539.0M508.0M463.0M
Selling, General & Administrative i2.3B2.2B2.0B2.0B1.7B
Other Operating Expenses i-----
Total Operating Expenses i3.0B2.8B2.5B2.5B2.2B
Operating Income i3.4B3.1B2.9B2.8B2.3B
Operating Margin % i36.6%35.9%36.2%36.0%34.0%
Non-Operating Items
Interest Income i106.0M105.0M50.0M6.0M12.0M
Interest Expense i225.0M239.0M221.0M224.0M231.0M
Other Non-Operating Income-140.0M1.0M-101.0M-97.0M-54.0M
Pre-tax Income i3.1B2.9B2.7B2.5B2.0B
Income Tax i637.0M596.0M545.0M454.0M360.0M
Effective Tax Rate % i20.3%20.3%20.5%18.2%18.0%
Net Income i2.5B2.3B2.1B2.0B1.6B
Net Margin % i27.0%27.4%26.1%26.2%24.5%
Key Metrics
EBITDA i4.0B3.7B3.5B3.3B2.7B
EPS (Basic) i$5.47$5.08$4.51$4.29$3.44
EPS (Diluted) i$5.47$5.07$4.49$4.27$3.42
Basic Shares Outstanding i454200000461172000468900000474300000475502000
Diluted Shares Outstanding i454200000461172000468900000474300000475502000

Income Statement Trend

Zoetis Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i2.0B2.0B3.6B3.5B3.6B
Short-term Investments i-----
Accounts Receivable i1.3B1.3B1.2B1.1B1.0B
Inventory i2.3B2.6B2.3B1.9B1.6B
Other Current Assets377.0M434.0M365.0M389.0M366.0M
Total Current Assets i6.0B6.3B7.5B6.9B6.6B
Non-Current Assets
Property, Plant & Equipment i219.0M230.0M220.0M181.0M192.0M
Goodwill i6.6B6.9B6.9B6.8B7.1B
Intangible Assets i1.1B1.3B1.4B1.5B1.7B
Long-term Investments-----
Other Non-Current Assets790.0M412.0M320.0M211.0M200.0M
Total Non-Current Assets i8.3B7.9B7.4B7.0B7.0B
Total Assets i14.2B14.3B14.9B13.9B13.6B
Liabilities
Current Liabilities
Accounts Payable i433.0M411.0M405.0M436.0M457.0M
Short-term Debt i1.4B3.0M1.4B-604.0M
Current Portion of Long-term Debt-----
Other Current Liabilities125.0M102.0M97.0M67.0M93.0M
Total Current Liabilities i3.4B1.9B3.2B1.8B2.2B
Non-Current Liabilities
Long-term Debt i5.4B6.8B6.7B6.7B6.8B
Deferred Tax Liabilities i167.0M146.0M142.0M320.0M378.0M
Other Non-Current Liabilities222.0M237.0M217.0M239.0M270.0M
Total Non-Current Liabilities i6.1B7.4B7.4B7.6B7.7B
Total Liabilities i9.5B9.3B10.5B9.4B9.8B
Equity
Common Stock i5.0M5.0M5.0M5.0M5.0M
Retained Earnings i12.0B10.3B8.7B7.2B5.7B
Treasury Stock i7.4B5.6B4.5B3.0B2.2B
Other Equity-----
Total Shareholders Equity i4.8B5.0B4.4B4.5B3.8B
Key Metrics
Total Debt i6.7B6.8B8.1B6.7B7.4B
Working Capital i2.6B4.5B4.3B5.1B4.4B

Balance Sheet Composition

Zoetis Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i2.5B2.3B2.1B2.0B1.6B
Depreciation & Amortization i497.0M491.0M465.0M448.0M441.0M
Stock-Based Compensation i74.0M60.0M62.0M58.0M59.0M
Working Capital Changes i79.0M-512.0M-699.0M-343.0M-85.0M
Operating Cash Flow i2.8B2.3B1.7B2.1B2.0B
Investing Activities
Capital Expenditures i-----
Acquisitions i285.0M-59.0M-312.0M-14.0M-113.0M
Investment Purchases i-5.0M-4.0M-9.0M-12.0M-27.0M
Investment Sales i62.0M12.0M23.0M44.0M0
Investing Cash Flow i340.0M-45.0M-297.0M19.0M-119.0M
Financing Activities
Share Repurchases i-1.9B-1.1B-1.6B-743.0M-250.0M
Dividends Paid i-786.0M-692.0M-611.0M-474.0M-380.0M
Debt Issuance i001.3B01.2B
Debt Repayment i0-1.4B0-600.0M-500.0M
Financing Cash Flow i-2.7B-3.1B-866.0M-1.8B103.0M
Free Cash Flow i2.3B1.6B1.3B1.7B1.7B
Net Change in Cash i490.0M-871.0M503.0M310.0M2.0B

Cash Flow Trend

Zoetis Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 25.36
Forward P/E 23.24
Price to Book 13.14
Price to Sales 6.96
PEG Ratio 23.24

Profitability Ratios

Profit Margin 27.83%
Operating Margin 40.20%
Return on Equity 52.77%
Return on Assets 15.37%

Financial Health

Current Ratio 1.76
Debt to Equity 137.01
Beta 0.88

Per Share Data

EPS (TTM) $5.81
Book Value per Share $11.21
Revenue per Share $20.90

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
zts65.3B25.3613.1452.77%27.83%137.01
Haleon Plc - ADR 43.6B21.445.449.38%13.81%53.41
Intra-Cellular 14.0B-183.1512.20-8.58%-10.97%1.48
United Therapeutics 13.6B11.761.9019.30%40.36%0.00
Neurocrine 13.1B38.944.8413.39%13.88%18.18
Viatris 12.5B235.800.80-19.77%-24.57%94.78

Financial data is updated regularly. All figures are in the company's reporting currency.